ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker. The drug, called evorpacept, is in a pair of phase 2 trials for ...

ALX Oncology’s phase 2 gastric cancer response rate has weakened. After seeing its CD47 blocker easily beat control over the first half of the trial, the biotech reported a much closer fight in ...

The quickly rising singer ALX dropped a pop-infused new single and video for his latest single, “Run Out.” Other scenes involve the artist lying with his hands bound in a field, getting a ...

Chief Medical Officer of ALX Oncology, Dr. Alan Sandler, underlined the design of the treatment, which combines anti-HER2 antibodies efficiently to improve results. For the second-line treatment ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...

A copy of the poster presentation will be available on the Publications section of ALX Oncology’s website at the start of the presentation at SABCS on December 12, 2024.

VANCOUVER, British Columbia & BURLINGAME, Calif.--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional ...